Agents acting on central dopamine receptors.
D015081:2-Naphthylamine / Q000031:analogs & derivatives / Q000494:pharmacology; D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001058:Apomorphine / Q000031:analogs & derivatives / Q000494:pharmacology; D001567:Benzocycloheptenes / Q000378:metabolism; D001665:Binding Sites; D001921:Brain / Q000378:metabolism*; D002069:Butaclamol / Q000494:pharmacology; D002090:Butyrophenones / Q000494:pharmacology; D004298:Dopamine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D005116:Extrapyramidal Tracts / Q000187:drug effects; D006220:Haloperidol / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D008968:Molecular Conformation; D009474:Neurons / Q000502:physiology; D010640:Phenothiazines; D011719:Pyrazines / Q000378:metabolism; D011954:Receptors, Dopamine / Q000187:drug effects*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D013569:Synapses / Q000378:metabolism
D014150:Antipsychotic Agents; D001567:Benzocycloheptenes; D002090:Butyrophenones; D007211:Indoles; D007546:Isoquinolines; D010640:Phenothiazines; D011719:Pyrazines; D011954:Receptors, Dopamine; D002069:Butaclamol; D015081:2-Naphthylamine; D000262:Adenylyl Cyclases; D006220:Haloperidol; D001058:Apomorphine; D004298:Dopamine